Ypsilon Therapeutics

Ypsilon Therapeutics, a portfolio company of Alloy Therapeutics' venture studio 82VS, is developing the next generation of T-cell receptor mimics (TCRm) antibodies. Ypsilon Therapeutics' mission is to leverage the specificity of TCR interactions with proteins on the surface of cancer cells to enable new approaches for targeting and treating cancer with high precision and efficacy.